Ancora.ai Clinical Trial Navigator
ancoraai.bsky.social
Ancora.ai is an AI-enabled digital platform that enables cancer patients & their care teams to find trials. We believe technology can help improve access and make clinical trial navigation more efficient and effective. Check out the tool at www.ancora.ai
👤 Joined on 11 November 2024
55
Followers
175
Following
31
Total Posts
📜 Kullanıcı Geçmişi
- 11 Kas 2024, 17:17
🎉 Bluesky'e katıldı - İlk kullanıcı adı:
@ancoraai.bsky.social
🚫 Blokladığı Kullanıcılar
❤️ Beğendiği Gönderiler
🧬 Researchers at @wakeforestmed.bsky.social identified a protein that may help breast cancer spread to the brain and evade immune defenses. #bcsm #oncology Read more ➡️: www.onclive.com/view/researc...
Show Post
💬 "Para nosotros es muy importante dar el mensaje de todo lo que puede hacer la sociedad en su conjunto para intentar evitar factores de cáncer." Este fue el mensaje principal de la cuarta #VHIOTalks26, con Marcos Malumbres, José Antonio Seoane y moderada por Luis Quevedo. #SOMMVHIO #20VHIO
Show Post🎥 WATCH: Alexander N. Shoushtari, MD, of @mskcancercenter.bsky.social, discusses the current role, benefits, and limitations of monitoring ctDNA in metastatic uveal melanoma. #melsm #oncology Full video ➡️: www.onclive.com/view/dr-shou...
Show Post
Join @danafarber.bsky.social and @pennmedicine.bsky.social for a hybrid CME: The Older Adult with Cancer on Friday, October 16 as we discuss the latest advancements in personalized care and comprehensive assessments for older adults with cancer. Register: www.med.upenn.edu/Gerionc2026/
Show Post
When it comes to dosimetry, Dr. Richard Wahl thinks we can do better. His article in the JNM Theranostics Supplement, co-written with Dr. Yuni K. Dewaraja, makes the case against a “one dose fits all strategy.” jnm.snmjournals.org/content/67/S...
Show Post